Single MVA-SARS-2-ST/N Vaccination Rapidly Protects K18-hACE2 Mice against a Lethal SARS-CoV-2 Challenge Infection
Viruses · 2024
DOI: 10.3390/v16030417 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Sabrina Clever und 15 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Virology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, gamma-Globulins, Melphalan. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Culture of Lower Saxony, Deutsche Forschungsgemeinschaft, Bayerischer Forschungsverbund FOR-COVID.
Abstract (Originalsprache)
The sudden emergence of SARS-CoV-2 demonstrates the need for new vaccines that rapidly protect in the case of an emergency. In this study, we developed a recombinant MVA vaccine co-expressing SARS-CoV-2 prefusion-stabilized spike protein (ST) and SARS-CoV-2 nucleoprotein (N, MVA-SARS-2-ST/N) as an approach to further improve vaccine-induced immunogenicity and efficacy. Single MVA-SARS-2-ST/N vaccination in K18-hACE2 mice induced robust protection against lethal respiratory SARS-CoV-2 challenge infection 28 days later. The protective outcome of MVA-SARS-2-ST/N vaccination correlated with the activation of SARS-CoV-2-neutralizing antibodies (nABs) and substantial amounts of SARS-CoV-2-specific T cells especially in the lung of MVA-SARS-2-ST/N-vaccinated mice. Emergency vaccination with MVA-SARS-2-ST/N just 2 days before lethal SARS-CoV-2 challenge infection resulted in a delayed onset of clinical disease outcome in these mice and increased titers of nAB or SARS-CoV-2-specific T cells in the spleen and lung. These data highlight the potential of a multivalent COVID-19 vaccine co-expressing S- and N-protein, which further contributes to the development of rapidly protective vaccination strategies against emerging pathogens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Virology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany.
- Division of Virology, Department of Veterinary Sciences, LMU Munich, 85764 Oberschleißheim, Germany.
- Department of Pathology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany.
ORCID-Profile: Georg Beythien, Malgorzata Rosiak, Kirsten Hülskötter, Katharina Manuela Gregor, Georgia Kalodimou, Satendra Kumar, Wolfgang Baumgärtner, Gerd Sutter, Alina Tscherne, Asisa Volz
Förderung
- Ministry of Science and Culture of Lower Saxony
- Deutsche Forschungsgemeinschaft
- Bayerischer Forschungsverbund FOR-COVID
- Ministry of Science and Culture of Lower Saxony, Germany
- DFG
- COVID
Zitieren
APA
Clever, S., Limpinsel, L., Meyer Zu Natrup, C., Schünemann, L. M., Beythien, G., Rosiak, M., Hülskötter, K., Gregor, K. M., Tuchel, T., Kalodimou, G., Freudenstein, A., Kumar, S., Baumgärtner, W., Sutter, G., Tscherne, A., & Volz, A. (2024). Single MVA-SARS-2-ST/N Vaccination Rapidly Protects K18-hACE2 Mice against a Lethal SARS-CoV-2 Challenge Infection. Viruses. https://doi.org/10.3390/v16030417
Vancouver
Clever S, Limpinsel L, Meyer Zu Natrup C, Schünemann LM, Beythien G, Rosiak M, et al. Single MVA-SARS-2-ST/N Vaccination Rapidly Protects K18-hACE2 Mice against a Lethal SARS-CoV-2 Challenge Infection. Viruses. 2024. doi:10.3390/v16030417
BibTeX
@article{Clever2024,
author = {Clever, Sabrina and Limpinsel, Leonard and Meyer Zu Natrup, Christian and Schünemann, Lisa-Marie and Beythien, Georg and Rosiak, Malgorzata and Hülskötter, Kirsten and Gregor, Katharina Manuela and Tuchel, Tamara and Kalodimou, Georgia and Freudenstein, Astrid and Kumar, Satendra and Baumgärtner, Wolfgang and Sutter, Gerd and Tscherne, Alina and Volz, Asisa},
title = {Single MVA-SARS-2-ST/N Vaccination Rapidly Protects K18-hACE2 Mice against a Lethal SARS-CoV-2 Challenge Infection},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16030417}
}
EUVIMED